PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q82088

Atsuro NAKAZATO, et al.

Appln. No.: 10/500,101

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: June 25, 2004

For:

6-FLUOROBICYCLO [3.1.0] HEXANE DERIVATIVES

<u>UNDER 37 C.F.R. §§ 1.97 and 1.98</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Q82088

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/500,101

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: September 30, 2004

	Substitute for Form 1449 A & 16/PTO		Conf	plete if Known	
			Application Number	10/500,101	
б	INFORMATION DISC	LOSURE	Confirmation Number	Not Yet Assigned	
1	STATEMENT BY APP		Filing Date	June 25, 2004	
SEP	20/		First Named Inventor	Atsuro NAKAZATO	
	30 2004 (use as many sheets as ne	cessary)	Art Unit	Not Yet Assigned	
		• •	Examiner Name	Not Yet Assigned	
	Sheet 1	of 1	Attorney Docket Number	Q82088	
Ś	Dennis				

U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number		Publication Date				
Initials*	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
·								

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
 				-			
							_
			· <u> </u>				

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶			
		SHIGETADA NAKANISHI, et al. "Molecular Diversity of Glutamate Receptors and Implications for Brain Function", Science, October 23, 1992, Vol. 258, pp. 597-603				
		YASUTO TANABE, et al. "Signal Transduction, Pharmacological Properties, and Expression Patterns of Two Rat Metabotropic Glutamate Receptors, mGluR3 and mGluR4", The Journal of Neuroscience, April 1993, 13(4): 1372-1378				
		J.P. PIN, et al. "Review: Neurotransmitter receptors I The Metabotropic Glutamate Receptors: Structure and Functions", Neuropharmacology, 1995, Vol. 34, No. 1, pp. 1-26				
		DARRYLE D. SCHOEPP, et al. "Metabotropic glutamate receptors in brain function and pathology", Trends Pharmacol. January 1993, Vol. 14, pp. 13-20				

	i		ł –	
	i			
E	4 ·	Date Considered	į.	
Examiner Signature	i e e e e e e e e e e e e e e e e e e e	Date Considered	l	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.